Amgen Inc.

The Scripps Research Institute

Guo-Qiang Cao

Christopher Michael Tegley

Celia Dominguez

Matthew W Martin

Craig E Masse

Andrew Stewart Tasker

Kyriacos Costa Nicolaou

Joseph L Kim

Jean-Christophe P Harmange

Brian K Albrecht

Vinod Francis Patel

Jean E Bemis

Jennifer Rebecca Allen

Brian Lewis Hodous

Anthony B Reed

Kaustav Biswas

Robert Michael Rzasa

Ryan D White

Victor J Cee

Roland W Burli

Dawei Zhang

Jennifer Elizabeth Golden

Michael J Frohn

Alexander J Pickrell

Liping H Pettus

Shimin Xu

Nuria A Tamayo

Steven F Bellon

Russell Graceffa

James Richard Falsey

Randall W Hungate

Adrian Leonard Smith

Stuart C Chaffee

Paul A Tempest

Fang-Tsao Hong

Philip R Olivieri

Gregory J Habgood

Nick A Paras

Susana C Neira

Stephanie J Mercede

Bradley J Herberich

Holly L Deak

Marian C Bryan

Kelvin K C Sham

Tanya Peterkin

Xiang Wang

Seifu Tadesse

Partha P Chakrabarti

William H Buckner

Hongyu Liao

Kurt E Weiler

Martin H Goldberg

Anthony Roecker

Maya C Thaman

Jeffrey Pfefferkorn

Kelvin Sham

Stephanie D Geuns-Meyer

John L Buchanan

David C Mcgowan

Susan Ann Tomlinson

Erin F Dimauro

Frenel F Demorin

Kelvin KC Sham

Partha Pratim Chakrabarti

Roland Burli

Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

Azaquinolones that inhibit prolyl hydroxylase

are useful as inhibitors of HIF prolyl hydroxylases where the definitions of the variables are provided herein.

Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof

Quinolones and azaquinolones that inhibit prolyl hydroxylase

Compounds of Formula I and Formula II are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein B, R, R, R, Rand Rare d.efined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

Phthalazine compounds and methods of use

Benzopyran-based inhibitors of NADH:ubiquinone oxidoreductase for inhibiting the growth of cancer cells.

Inhibitors of NADH:ubiquinone oxidoreductase

The present invention relates to compounds having the general formulaor a pharmaceutically acceptable salt thereof, wherein Ris a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein Ris additionally substituted; and Ris a substituted Calkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic &#x3b2; cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general formulaor a pharmaceutically acceptable salt thereof. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic &#x3b2; cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

Growing community of inventors

Thousand Oaks, CA, United States of America

Guo-Qiang Cao